US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Blossomhill Therapeutics / Equity Capital Markets

<ul>
<li>BlossomHill upsized its IPO 20% but opened 1.6% below issue, suggesting the enlarged deal stretched underlying demand.</li>
<li>BH-30643 remains the primary value driver, targeting resistant EGFR-mutant NSCLC, including the underserved C797S-positive population.</li>
<li>The stock closed at its $16 IPO price, but persistent intraday weakness suggests investors may need patience as clinical catalysts develop.</li>
</ul>


BlossomHill upsized its IPO 20% but opened 1.6% below issue, suggesting the enlarged deal stretched underlying demand.
BH-30643 remains the primary value driver, targeting resistant EGFR-mutant NSCLC, including the underserved C797S-positive population.
The stock closed at its $16 IPO price, but persistent intraday weakness suggests investors may need patience as clinical catalysts develop.


BlossomHill Therapeutics (BLSM): IPO Falls Flat After Aggressive Upsizing

<ul>
<li>Lead candidate BH-30643 targets multiple EGFR mutations, with C797S-positive NSCLC offering a differentiated opportunity where no targeted therapy is currently approved.</li>
<li>A broader oncology pipeline provides additional optionality, with BH-30236 in Phase 1 and pan-KRAS candidate BH-501284 approaching a planned 2027 IND.</li>
<li>Cormorant, OrbiMed, Vivo Innovation and Janus Henderson highlight a strong pre-IPO shareholder roster, adding credibility to an otherwise high-risk early-stage biotech offering.</li>
</ul>


Lead candidate BH-30643 targets multiple EGFR mutations, with C797S-positive NSCLC offering a differentiated opportunity where no targeted therapy is currently approved.
A broader oncology pipeline provides additional optionality, with BH-30236 in Phase 1 and pan-KRAS candidate BH-501284 approaching a planned 2027 IND.
Cormorant, OrbiMed, Vivo Innovation and Janus Henderson highlight a strong pre-IPO shareholder roster, adding credibility to an otherwise high-risk early-stage biotech offering.


BlossomHill Therapeutics (BLSM): Demand Blossoms as Books Near the Finish Line

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>San Diego-based BlossomHill Therapeutics has filed for a Nasdaq IPO seeking to raise approximately $125 million through the sale of 7.81 million shares priced between $15.00 and $17.00 each.</li><li>At the midpoint of the proposed range, the company would have an implied market capitalization of approximately $465 million.</li><li>BlossomHill intends to trade on the Nasdaq Global Select Market under the ticker BLSM, with the offering being led by J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, and H.C. Wainwright &amp; Co.</li></ul>

San Diego-based BlossomHill Therapeutics has filed for a Nasdaq IPO seeking to raise approximately $125 million through the sale of 7.81 million shares priced between $15.00 and $17.00 each.At the midpoint of the proposed range, the company would have an implied market capitalization of approximately $465 million.BlossomHill intends to trade on the Nasdaq Global Select Market under the ticker BLSM, with the offering being led by J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, and H.C. Wainwright &amp; Co.

BlossomHill Therapeutics (BLSM) Targets $125 Million IPO to Advance Precision Oncology Pipeline

<ul><li>BlossomHill Therapeutics is expected to list on the Nasdaq under the ticker BLSM, offering 7.82 million shares at a price range of $15.00 to $17.00 per share and targeting approximately $125 million in gross proceeds.</li><li>The company is developing next-generation macrocyclic small-molecule oncology therapies designed to overcome resistance mechanisms in EGFR-mutant cancers.</li><li>Its lead candidate, BH-30643, is being evaluated in a global Phase 1/2 study targeting patients with EGFR-mutant non-small cell lung cancer, including difficult-to-treat resistance mutations.</li></ul>

BlossomHill Therapeutics is expected to list on the Nasdaq under the ticker BLSM, offering 7.82 million shares at a price range of $15.00 to $17.00 per share and targeting approximately $125 million in gross proceeds.The company is developing next-generation macrocyclic small-molecule oncology therapies designed to overcome resistance mechanisms in EGFR-mutant cancers.Its lead candidate, BH-30643, is being evaluated in a global Phase 1/2 study targeting patients with EGFR-mutant non-small cell lung cancer, including difficult-to-treat resistance mutations.

IPO Rating: BlossomHill Therapeutics (BLSM)

<ul>
<li>BlossomHill is advancing a precision oncology pipeline led by BH-30643, an OMNI-EGFR inhibitor targeting resistant EGFR-mutant NSCLC populations.</li>
<li>IPO proceeds will primarily fund BH-30643’s Phase 1/2 SOLARA trial and potential registrational Phase 2 development pathway.</li>
<li>Backed by notable biotech investors, BlossomHill enters public markets as an early-stage oncology company with significant clinical execution risk and upside potential.</li>
</ul>


BlossomHill is advancing a precision oncology pipeline led by BH-30643, an OMNI-EGFR inhibitor targeting resistant EGFR-mutant NSCLC populations.
IPO proceeds will primarily fund BH-30643’s Phase 1/2 SOLARA trial and potential registrational Phase 2 development pathway.
Backed by notable biotech investors, BlossomHill enters public markets as an early-stage oncology company with significant clinical execution risk and upside potential.


BlossomHill Therapeutics (BLSM): Phase 1/2 Lung Cancer Biotech Sets Terms for IPO, Debuting Friday

United States

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. The Company develops small molecule medicines that address unmet medical needs in cancer treatment. Blossomhill Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Blossomhill Therapeutics (BLSM US)

BlossomHill Therapeutics (BLSM): IPO Falls Flat After Aggressive Upsizing

BlossomHill's IPO upsized but opened below issue, BH-30643 key value driver targeting resistant NSCLC, stock closed at IPO price with intraday...

IPO Boutique

BlossomHill Therapeutics (BLSM): Demand Blossoms as Books Near the Finish Line

Lead candidate BH-30643 targets multiple EGFR mutations in NSCLC, offering a unique opportunity in a field lacking approved targeted therapy....

IPO Boutique

BlossomHill Therapeutics (BLSM) Targets $125 Million IPO to Advance Precision Oncology Pipeline

San Diego-based BlossomHill Therapeutics has filed for a Nasdaq IPO seeking to raise approximately $125 million through the sale of 7.81 million...

IPO Prophet

IPO Rating: BlossomHill Therapeutics (BLSM)

BlossomHill Therapeutics is expected to list on the Nasdaq under the ticker BLSM, offering 7.82 million shares at a price range of $15.00 to...

IPO Prophet

BlossomHill Therapeutics (BLSM): Phase 1/2 Lung Cancer Biotech Sets Terms for IPO, Debuting Friday

BlossomHill's precision oncology pipeline, led by BH-30643, targets resistant EGFR-mutant NSCLC populations with IPO proceeds funding Phase 1/2...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

BlossomHill Therapeutics (BLSM): IPO Falls Flat After Aggressive Upsizing

​BlossomHill's IPO upsized but opened below issue, BH-30643 key value driver targeting resistant NSCLC, stock closed at IPO price with intraday...

IPO Boutique

BlossomHill Therapeutics (BLSM): Demand Blossoms as Books Near the Finish Line

​Lead candidate BH-30643 targets multiple EGFR mutations in NSCLC, offering a unique opportunity in a field lacking approved targeted therapy....

IPO Boutique

BlossomHill Therapeutics (BLSM) Targets $125 Million IPO to Advance Precision Oncology Pipeline

San Diego-based BlossomHill Therapeutics has filed for a Nasdaq IPO seeking to raise approximately $125 million through the sale of 7.81 million...

IPO Prophet

IPO Rating: BlossomHill Therapeutics (BLSM)

BlossomHill Therapeutics is expected to list on the Nasdaq under the ticker BLSM, offering 7.82 million shares at a price range of $15.00 to...

IPO Prophet

BlossomHill Therapeutics (BLSM): Phase 1/2 Lung Cancer Biotech Sets Terms for IPO, Debuting Friday

​BlossomHill's precision oncology pipeline, led by BH-30643, targets resistant EGFR-mutant NSCLC populations with IPO proceeds funding Phase 1/2...

IPO Boutique

BlossomHill's IPO upsized but opened below issue, BH-30643 key value driver targeting resistant NSCLC, stock closed at IPO price with intraday...

Lead candidate BH-30643 targets multiple EGFR mutations in NSCLC, offering a unique opportunity in a field lacking approved targeted therapy....

BlossomHill's precision oncology pipeline, led by BH-30643, targets resistant EGFR-mutant NSCLC populations with IPO proceeds funding Phase 1/2...